Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine for cognitive impairment after COVID-19
IRCT20090117001556N138Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of famotidine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of cognitive impairments. Started Sep 2021; status: completed.
02
Drugs
famotidine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20090117001556N138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N138.